Fight Colorectal Cancer launches its fifth annual United in Blue installation on the National Mall from March 1-14, 2026, featuring over 27,000 blue flags representing people under 50 projected to be diagnosed with colorectal cancer in 2030. The installation comes as new American Cancer Society research confirms colorectal cancer has become the deadliest cancer for Americans under 50, with mortality increasing in 2025.

Ahead of the March 6, 2026 FDA decision on Bristol Myers Squibb's Sotyktu (deucravacitinib) for psoriatic arthritis, a survey of 104 U.S. rheumatologists shows strong pre-launch awareness with one-third viewing it as a substantial advance. However, BMS ranks lowest among major pharmaceutical partners in rheumatology and is expected to capture roughly one-fifth of PsA patients through brand-to-brand share shifts rather than market expansion. The launch represents a critical opportunity for BMS to strengthen its standing in the specialty.

The global medical device cleaning market is projected to grow from USD 2.08 billion in 2024 to USD 3.74 billion by 2032, driven by escalating infection prevention requirements, expanding reusable device utilization, and technological advancements in automated reprocessing systems. However, high capital costs, complex regulatory obligations, and workforce training variability pose challenges to uniform adoption across regions.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

Johnson & Johnson is outperforming the volatile tech sector, trading near all-time highs of $245 per share with a 14% gain over 30 days. The healthcare giant's appeal lies in its 64-year dividend growth streak, low volatility (Beta of 0.35), strong free cash flow of $21 billion, and strategic pivot toward high-growth pharmaceuticals and medical technology. The company projects $100 billion in revenue for 2026 with new blockbuster drugs like Darzalex and Tremfya offsetting patent cliff losses, while potential divestiture of its orthopedics unit could further improve margins.

ACR Alpine Capital Research acquired 1,028,778 shares of Arrow Electronics in Q4 2025, increasing its position to 5.9% of AUM valued at $379 million. The purchase aligns with Arrow Electronics' recovery, with full-year revenue growing 10% to over $30 billion, and reflects confidence in the company's positioning amid broader manufacturing sector improvement.

While the S&P 500 remains flat year-to-date, value-focused Vanguard ETFs are outperforming due to strength in financials, industrials, energy, and materials sectors. The Vanguard Value ETF (VTV), Mega Cap Value ETF (MGV), and High Dividend Yield ETF (VYM) offer different approaches to value investing with low expense ratios and attractive dividend yields compared to the broader market.

Johnson & Johnson is highlighted as a strong anchor for retirement portfolios due to its Dividend King status with 63 consecutive years of dividend increases. The company benefits from its leadership position in the multitrillion-dollar global healthcare industry, strong financials, AAA credit rating, and potential for double-digit growth acceleration by the end of the decade.

Johnson & Johnson is preparing to sell its orthopedics unit DePuy Synthes as part of its planned business separation announced in October 2025. The unit, acquired for $21.3 billion in 2011, generated $9.3 billion in annual sales and could be valued at $20-28 billion. Multiple private equity firms are reportedly considering joint bids, with discussions expected in coming weeks. J&J beat Q4 2025 earnings expectations and raised 2026 guidance.

A phase 3 clinical trial (LATITUDE) published in NEJM demonstrates that long-acting injectable cabotegravir and rilpivirine is superior to daily oral antiretroviral therapy for HIV patients with adherence challenges. The long-acting treatment showed a regimen failure rate of 22.8% compared to 41.2% for daily oral ART over 48 weeks, with similar side effect profiles between groups.

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

The Trial Lawyer Hall of Fame announced the induction of four prominent trial attorneys—Christopher M. Placitella, Daniel E. Rosner, Robert T. Eglet, and Thomas R. Kline—into its 2026 class. The inductees will be honored at the MTMP Spring 2026 mass torts conference in Las Vegas, April 15-17. The honorees are recognized for their exceptional courtroom achievements, including record-setting verdicts and settlements, and their contributions to advancing the civil justice system.